These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 38443644)

  • 1. Transcriptomics-driven metabolic pathway analysis reveals similar alterations in lipid metabolism in mouse MASH model and human.
    Tsouka S; Kumar P; Seubnooch P; Freiburghaus K; St-Pierre M; Dufour JF; Masoodi M
    Commun Med (Lond); 2024 Mar; 4(1):39. PubMed ID: 38443644
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Spatial lipidomics reveals zone-specific hepatic lipid alteration and remodeling in Metabolic dysfunction-associated steatohepatitis.
    Seubnooch P; Montani M; Dufour JF; Masoodi M
    J Lipid Res; 2024 Jul; ():100599. PubMed ID: 39032559
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Probiotic Mixture Ameliorates a Diet-Induced MASLD/MASH Murine Model through the Regulation of Hepatic Lipid Metabolism and the Gut Microbiome.
    Zhang F; Lo EKK; Chen J; Wang K; Felicianna ; Ismaiah MJ; Leung HKM; Zhao D; Lee JC; El-Nezami H
    J Agric Food Chem; 2024 Apr; 72(15):8536-8549. PubMed ID: 38575146
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Time-of-day-dependent variation of the human liver transcriptome and metabolome is disrupted in MASLD.
    Johanns M; Haas JT; Raverdy V; Vandel J; Chevalier-Dubois J; Guille L; Derudas B; Legendre B; Caiazzo R; Verkindt H; Gnemmi V; Leteurtre E; Derhourhi M; Bonnefond A; Froguel P; Eeckhoute J; Lassailly G; Mathurin P; Pattou F; Staels B; Lefebvre P
    JHEP Rep; 2024 Jan; 6(1):100948. PubMed ID: 38125300
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sex-based differences in natural killer T cell-mediated protection against diet-induced steatohepatitis in Balb/c mice.
    Cuño-Gómiz C; de Gregorio E; Tutusaus A; Rider P; Andrés-Sánchez N; Colell A; Morales A; Marí M
    Biol Sex Differ; 2023 Nov; 14(1):85. PubMed ID: 37964320
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Lasting Effects of COVID-19 on the Progression of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD).
    Backer S; Khanna D
    Cureus; 2023 Sep; 15(9):e45231. PubMed ID: 37842470
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Choline-deficient high-fat diet-induced MASH in Göttingen Minipigs: Characterisation and effects of a chow reversal period.
    Hvid H; Hjuler ST; Bedossa P; Tiniakos DG; Kamzolas I; Harder LM; Xue Y; Perfield JW; Kirk RK; Latta M; Mikkelsen LF; Pedersen HD
    Am J Physiol Gastrointest Liver Physiol; 2024 Jul; ():. PubMed ID: 39041677
    [TBL] [Abstract][Full Text] [Related]  

  • 8. NIS2+
    Ratziu V; Harrison SA; Hajji Y; Magnanensi J; Petit S; Majd Z; Delecroix E; Rosenquist C; Hum D; Staels B; Anstee QM; Sanyal AJ
    J Hepatol; 2024 Feb; 80(2):209-219. PubMed ID: 38061448
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genetic Ablation of STE20-Type Kinase MST4 Does Not Alleviate Diet-Induced MASLD Susceptibility in Mice.
    Caputo M; Andersson E; Xia Y; Hou W; Cansby E; Erikson M; Lind DE; Hallberg B; Amrutkar M; Mahlapuu M
    Int J Mol Sci; 2024 Feb; 25(4):. PubMed ID: 38397122
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increased hepatic putrescine levels as a new potential factor related to the progression of metabolic dysfunction-associated steatotic liver disease.
    Núñez-Sánchez MÁ; Martínez-Sánchez MA; Sierra-Cruz M; Lambertos A; Rico-Chazarra S; Oliva-Bolarín A; Balaguer-Román A; Yuste JE; Martínez CM; Mika A; Frutos MD; Llamoza-Torres CJ; Córdoba-Chacón J; Ramos-Molina B
    J Pathol; 2024 Jul; ():. PubMed ID: 39022853
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comprehensive meta-analysis reveals distinct gene expression signatures of MASLD progression.
    Piras IS; DiStefano JK
    Life Sci Alliance; 2024 Jun; 7(6):. PubMed ID: 38565287
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined, elobixibat, and colestyramine reduced cholesterol toxicity in a mouse model of metabolic dysfunction-associated steatotic liver disease.
    Iwaki M; Kessoku T; Tanaka K; Ozaki A; Kasai Y; Kobayashi T; Nogami A; Honda Y; Ogawa Y; Imajo K; Usuda H; Wada K; Kobayashi N; Saito S; Nakajima A; Yoneda M
    Hepatol Commun; 2023 Nov; 7(11):. PubMed ID: 37902528
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Τ cell-mediated adaptive immunity in the transition from metabolic dysfunction-associated steatohepatitis to hepatocellular carcinoma.
    Papadopoulos G; Giannousi E; Avdi AP; Velliou RI; Nikolakopoulou P; Chatzigeorgiou A
    Front Cell Dev Biol; 2024; 12():1343806. PubMed ID: 38774646
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic implications for sphingolipid metabolism in metabolic dysfunction-associated steatohepatitis.
    Ramos-Molina B; Rossell J; Pérez-Montes de Oca A; Pardina E; Genua I; Rojo-López MI; Julián MT; Alonso N; Julve J; Mauricio D
    Front Endocrinol (Lausanne); 2024; 15():1400961. PubMed ID: 38962680
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lipid Metabolism in Metabolic-Associated Steatotic Liver Disease (MASLD).
    Syed-Abdul MM
    Metabolites; 2023 Dec; 14(1):. PubMed ID: 38248815
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dietary and pharmacological treatment in patients with metabolic-dysfunction associated steatotic liver disease.
    Armandi A; Bugianesi E
    Eur J Intern Med; 2024 Apr; 122():20-27. PubMed ID: 38262842
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Elevated expression of LCN13 through FXR activation ameliorates hepatocellular lipid accumulation and inflammation.
    Qin X; Tan Y; Ren W; Zhou W; Niu R; Liang L; Li J; Cao K; Wei G; Zhu X; Huang M
    Int Immunopharmacol; 2024 Apr; 131():111812. PubMed ID: 38493698
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Loss of mitochondrial adaptation associates with deterioration of mitochondrial turnover and structure in metabolic dysfunction-associated steatotic liver disease.
    Sarabhai T; Kahl S; Gancheva S; Mastrototaro L; Dewidar B; Pesta D; Ratter-Rieck JM; Bobrov P; Jeruschke K; Esposito I; Schlensak M; Roden M
    Metabolism; 2024 Feb; 151():155762. PubMed ID: 38122893
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hepatic glucose metabolism in the steatotic liver.
    Scoditti E; Sabatini S; Carli F; Gastaldelli A
    Nat Rev Gastroenterol Hepatol; 2024 May; 21(5):319-334. PubMed ID: 38308003
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Multicomponent Medicinal Product Hepar Compositum Reduces Hepatic Inflammation and Fibrosis in a Streptozotocin- and High-Fat Diet-Induced Model of Metabolic Dysfunction-Associated Steatotic Liver Disease/Metabolic Dysfunction-Associated Steatohepatitis.
    Burmeister Y; Weyer K; Dörre A; Seilheimer B
    Biomedicines; 2023 Dec; 11(12):. PubMed ID: 38137437
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.